-
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Recruiting
More
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
therapy.
Stanford Investigators
View full details
-
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
Not Recruiting
More
This is a prospective, multi-center, randomized, clinical trial evaluating patients
undergoing breast conserving surgery using the LUM Imaging System.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
Not Recruiting
More
Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption
or obstruction of the lymphatic system, which commonly occurs a result of breast cancer
therapy. The purpose of this study is to determine if the use of a low risk lymphatic
reconstruction procedure at the time of axillary lymph node dissection will reduce the risk
of developing lymphedema. Additionally, to determine if this procedure improves objective
outcomes of lymphedema and patient quality of life
Stanford is currently not accepting patients for this trial.
For more information, please contact Dung Nguyen, PharmD, 650-498-6004.
Lead Sponsor
Stanford Investigators
View full details
-
Investigation of Novel Surgical Imaging for Tumor Excision
Not Recruiting
More
This is a multi-center, two-arm randomized, blinded pivotal study to demonstrate the safety
and efficacy of the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM
Imaging Device and decision software), in identifying residual cancer in the lumpectomy bed
of female breast cancer patients undergoing breast surgery in order to assist surgeons in
reducing the rates of positive margins.
All enrolled subjects will be injected with LUM015 prior to surgery. Surgeons are blinded to
whether a participant will be randomized into the device arm until after the standard of care
lumpectomy is complete. Participants will then be randomized to receiving the device.
Therapeutic (LUM guided) shaves will be removed based on the guidance of the LUM Imaging
System. Patients will be followed until their first standard of care post-operative follow-up
visit.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Recruiting
More
This Phase III trial compares the recurrence-free interval (RFI) among patients with
early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive
HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus
those who are randomized to receive adjuvant radiotherapy per the standard of care.
Stanford Investigators
View full details
-
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Recruiting
More
The purpose of this pilot study is to compare by pathological findings surgical excision
versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in
situ (DCIS)
Lead Sponsor
Stanford Investigators
View full details
-
Intraoperative Detection of Residual Cancer in Breast Cancer
Not Recruiting
More
This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on
an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction
with the LUM imaging device), in identifying residual cancer in the tumor bed of female
breast cancer patients. During the study, study physicians and clinical staff will complete
hands-on training in anticipation of the upcoming pivotal study. Site-specific or
user-specific issues related to the use of the device will be identified and addressed.
Additionally, the data collected in the study will be used to continue training the tumor
detection algorithm of the device.
In this study, patients will be injected with LUM015 prior to surgery. The study physicians
will perform lumpectomy procedures according to his or her institution's standard of care
practice. After the main specimen removal is completed, the study physician will use the LUM
Imaging Device to image the tumor bed. Therapeutic shaves will be removed based on the
recommendation of the LUM Imaging System. Patients will be followed until their first
standard of care post-operative follow-up visit.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
Not Recruiting
More
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that
remain after surgery. It may also keep polyps from forming or colon cancer from coming back.
It is not yet known whether rosuvastatin is more effective than a placebo in treating colon
cancer that was removed by surgery.
PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works
compared with placebo in treating patients with stage I or stage II colon cancer that was
removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shannon Meyer, 6507241953.
Stanford Investigators
View full details
-
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Not Recruiting
More
The primary purpose of this study is to determine whether breast cancer tumors respond (as
measured by pathologic complete response: the absence of microscopic evidence of invasive
tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide)
followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients
with HER2-positive breast cancer. Trastuzumab will also be given to all patients after
surgery. The study will also evaluate the toxic effects of the chemotherapy combination,
including effects on the heart, and will determine survival and progression-free survival 5
years after treatment. Also, the study will look at whether there are gene expression
profiles in the tumor tissue that can predict pathologic complete response.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Not Recruiting
More
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is
not yet known whether letrozole is more effective than a placebo in treating patients with
hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works
compared with a placebo in treating postmenopausal women who have received hormone therapy
for hormone receptor-positive breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
Not Recruiting
More
The purpose of this study is to determine if Indocyanine Green (IC-GREEN) is comparable to
isosulfan blue (IS-BLUE) in the identification of arm lymphatics and arm-draining nodes
during nodal staging procedures in breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shannon Meyer, 650-724-1953.
Lead Sponsor
Stanford Investigators
View full details
-
Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
Not Recruiting
More
RATIONALE: Learning about how patients make decisions about using chemoprevention may help
doctors plan treatment in which more patients are willing to choose chemoprevention to reduce
their breast cancer risk.
PURPOSE: This clinical trial studies factors influencing decision-making about the use of
chemoprevention in women at increased risk for breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery
Not Recruiting
More
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting
pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving
surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy
destroyed the breast cancer cells and may be compared to the tumor removed during surgery to
check if they are the same.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Not Recruiting
More
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with
or without atezolizumab works in treating patients with breast cancer that has spread to
other parts of the body (metastatic). Chemotherapy drugs, such as paclitaxel, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted
therapy" because it works by attaching itself to specific molecules (receptors) on the
surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2
receptors, the signals that tell the cells to grow are blocked and the cancer cell may be
marked for destruction by the body's immune system. Monoclonal antibodies, such as
pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy
with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system
and may interfere with the ability of tumor cells to grow and spread. It is not yet known
whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill
more tumor cells.
*NOTE: This study has a central confirmation step. The purpose of this step is to confirm by
central testing that the patient's tumor has specific receptors. If the patient meets all the
study requirements, the patient will join the study and begin therapy for breast cancer while
the tumor is being tested.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
Not Recruiting
More
This is a treatment protocol designed to accompany the ongoing institutional 124I PET/CT
pilot imaging study for patients with invasive breast cancer. Women whose tumors express NIS
[Na+I- symporter, sodium iodide symporter] and demonstrate radioiodide uptake on 124I PET/CT
scans will be eligible for 131I treatment if, (1) tumor dosimetry calculations yield a
cumulative radiation dose of at least 30Gy in target tumor, (2) estimated cumulative thyroid
irradiation is less than 500 cGy and, (3) the therapeutic dose of 131I is in the range of 25
to 100 mCi.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Not Recruiting
More
In this study we plan to study the combination of ZD6474, a dual inhibitor of EGFR and
VEGFR-2 with anastrozole in the neoadjuvant setting for patients with Stage I-III breast
cancer. The aim is to overcome mechanisms of resistance and simultaneously block multiple
critical signaling pathways known to stimulate breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marcy Chen, 6507238686.
Lead Sponsor
Stanford Investigators
View full details
-
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Not Recruiting
More
The main purpose of this study is to learn if adding bevacizumab to standard treatment with
chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative
breast cancer will prevent breast cancer from returning. A second purpose of this study is to
learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative
breast cancer live longer. The researchers also want to learn about the side effects of the
combination of drugs used in this study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants
Not Recruiting
More
The investigators hope to learn the value of the SPY ELITE® intra-operative angiography in
reducing post-operative complications associated with low breast skin blood flow after breast
reconstruction using implants.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shannon Meyer, 650-724-1953.
Lead Sponsor
Stanford Investigators
View full details
-
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Not Recruiting
More
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function
suppression combined with hormone therapy using tamoxifen or exemestane may fight breast
cancer by reducing the production of estrogen. It is not yet known whether suppression of
ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone
in preventing the recurrence of hormone-responsive breast cancer.
PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or
exemestane to see how well they work compared to tamoxifen alone in treating premenopausal
women who have undergone surgery for hormone-responsive breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as capecitabine, fluorouracil, and oxaliplatin
work in different ways to stop tumor cells from dividing so they stop growing or die.
Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: This randomized phase III trial is studying radiation therapy and either
capecitabine or fluorouracil with or without oxaliplatin and comparing them to see how well
they work when given before surgery in treating patients with resectable rectal cancer. It is
not yet known whether radiation therapy and either capecitabine or fluorouracil is more
effective with or without oxaliplatin in treating rectal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
Not Recruiting
More
The purpose of this study is to examine breast cancers that express the protein (NIS) that
may be found in malignant breast tissues and to evaluate proteins found in blood and their
relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly
treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive
iodine entering breast cancer cells, how long your cancer retains the agent as well as how
much is taken up by other organs, particularly the thyroid gland.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Lead Sponsor
Stanford Investigators
View full details
-
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether chemotherapy is effective in treating
women who have undergone surgery and radiation therapy for relapsed breast cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy
in treating women who have undergone resection for local and/or regional relapsed breast
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide,
and doxorubicin, work in different ways to stop tumor cells from dividing so they stop
growing or die. It is not yet known which combination chemotherapy regimen is more effective
in treating breast cancer.
PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens to
compare how well they work in treating women who have undergone surgery for breast cancer
that has not spread to the lymph nodes.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Not Recruiting
More
This randomized phase III trial studies how well doxorubicin hydrochloride and
cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients
with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin
hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and
cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and
carboplatin in treating triple-negative breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Not Recruiting
More
This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent
breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shannon Meyer, .
Stanford Investigators
View full details
-
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Not Recruiting
More
The PENELOPEB study is designed to demonstrate that, in the background of standard
anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS)
compared to placebo in pre- and postmenopausal women with HR-positive/HER2-normal early
breast cancer at high risk of relapse after showing less than pathological complete response
to neoadjuvant taxane- containing chemotherapy. Considering the high risk of recurrence in
patients after neoadjuvant chemotherapy and a high CPS-EG score, palbociclib appears to be an
attractive option with a favourable safety profile for these patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Not Recruiting
More
Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to
approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or
subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of
local injection of plasmid IL-12 (pIL-12) followed immediately by electroporation (EP), into
accessible tumor lesions. IT-pIL12-EP will be administered in Days 1, 5, and 8 of the single
28-day cycle.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pei Jen Chang, 650-725-0866.
Stanford Investigators
View full details
-
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Not Recruiting
More
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab
after surgery to see how well they work in treating women with invasive breast cancer. Drugs
used in chemotherapy work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill
more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. It is not yet known
whether combination chemotherapy is more effective with trastuzumab in treating breast
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Not Recruiting
More
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab
emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer
who have residual tumor present in the breast or axillary lymph nodes following preoperative
therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6
mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or
hormone therapy will be given in addition if indicated.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Not Recruiting
More
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab
with estrogen deprivation to see how they work compared to docetaxel, carboplatin,
trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone
receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer
that is operable or has spread from where it started to nearby tissue or lymph nodes (locally
advanced). Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and
pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving more than
one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth
of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition
therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation
therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and
radiation therapy with or without hormone therapy may be an effective treatment for hormone
receptor-positive, HER2-positive, operable or locally advanced breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
Not Recruiting
More
The best available evidence suggests that pregnancy after breast cancer does not increase a
woman's risk of developing a recurrence from her breast cancer. In particular, the most
recent data suggest that this is the case also in women with a hormone receptor-positive
breast cancer. There is also no indication of increased risk for delivery complications or
for the newborn. The aim of the study is to investigate if temporary interruption of
endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of
breast cancer recurrence.The study aims also to evaluate different specific indicators
related to fertility, pregnancy and breast cancer biology in young women. A
psycho-oncological companion study on fertility concerns, psychological well-being and
decisional conflicts will be conducted in interested Centers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Not Recruiting
More
This randomized phase III trial studies the best individual therapy for women who have
node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype
DX), and whether hormone therapy alone or hormone therapy together with combination
chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen
can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by
blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the
body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving hormone therapy together with more than one chemotherapy drug (combination
chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the
benefit of adding chemotherapy to hormone therapy for women with node-negative,
estrogen-receptor positive breast cancer is small. New tests may provide information about
which patients are more likely to benefit from chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Florero Marilyn, 6507241953.
Stanford Investigators
View full details
-
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation
therapy in different ways may kill any tumor cells that remain after surgery. It is not yet
known whether whole breast radiation therapy is more effective than partial breast radiation
therapy in treating breast cancer.
PURPOSE: This randomized phase III trial is studying whole breast radiation therapy to see
how well it works compared to partial breast radiation therapy in treating women who have
undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 6507241953.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Not Recruiting
More
This randomized phase III trial studies radiation therapy to see how well it works with or
without trastuzumab in treating women with ductal carcinoma in situ who have undergone
lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy
x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective
with or without trastuzumab in treating ductal carcinoma in situ.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amy Isaacson, 650-723-0501.
Stanford Investigators
View full details
-
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast
cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs
in different combinations may kill more breast cancer cells. Giving combination chemotherapy
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy
regimens and their side effects and comparing how well they work in treating women with
non-metastatic breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Donna Adelman, 650-724-1953.
Stanford Investigators
View full details
